Organon & Co. (NYSE:OGN) Receives $8.50 Consensus Target Price from Analysts

Organon & Co. (NYSE:OGN) has earned a consensus rating of “Reduce” from the seven analysts that are currently covering the stock, Marketbeat reports. Five analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $8.50.

A number of equities analysts have recently issued reports on the company. Wall Street Zen downgraded Organon & Co. from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Barclays boosted their target price on Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a research note on Tuesday, February 24th. JPMorgan Chase & Co. decreased their price target on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a research note on Tuesday, November 11th. Zacks Research downgraded Organon & Co. from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Finally, Morgan Stanley dropped their price target on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 11th.

Institutional Investors Weigh In On Organon & Co.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Hantz Financial Services Inc. increased its position in shares of Organon & Co. by 293.8% in the 2nd quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company’s stock valued at $26,000 after acquiring an additional 1,995 shares during the period. Foster Dykema Cabot & Partners LLC purchased a new stake in Organon & Co. during the 3rd quarter valued at about $29,000. Farther Finance Advisors LLC increased its holdings in shares of Organon & Co. by 87.8% in the fourth quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock valued at $31,000 after purchasing an additional 2,033 shares during the period. SouthState Corp increased its holdings in shares of Organon & Co. by 1,857.0% in the second quarter. SouthState Corp now owns 3,914 shares of the company’s stock valued at $38,000 after purchasing an additional 3,714 shares during the period. Finally, Rothschild Investment LLC raised its stake in shares of Organon & Co. by 73.1% in the third quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock worth $42,000 after purchasing an additional 1,646 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Stock Performance

OGN stock opened at $6.88 on Monday. Organon & Co. has a one year low of $6.18 and a one year high of $16.08. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of 9.69, a PEG ratio of 0.63 and a beta of 0.60. The company has a debt-to-equity ratio of 11.47, a quick ratio of 1.23 and a current ratio of 1.82. The firm has a 50-day simple moving average of $7.99 and a two-hundred day simple moving average of $8.42.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, February 12th. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $0.73 by ($0.10). Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.The firm had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.52 billion. During the same quarter last year, the firm earned $0.90 EPS. The company’s revenue was down 5.3% compared to the same quarter last year. On average, equities analysts forecast that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 12th. Shareholders of record on Monday, February 23rd will be given a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Monday, February 23rd. Organon & Co.’s payout ratio is currently 11.27%.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.